Salute e Benessere

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed…

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed in all patients with 81% of EVX-01’s vaccine targets triggering a specific responseTreatment was well toleratedData is presented today at the ESMO Congress and will be discussed at a webinar with key opinion leader Professor Muhammad Adnan Khattak on October 22, 2025...

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of…

After 5 years, Kisqali ®plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival 1 Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease 1 Data also show a 29.1% risk reduction in distant disease-free survival, and a positive trend in...

Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat…

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant improvements in bleeding, quality of life measures, and other ITP symptoms If approved, Wayrilz will be the first BTK inhibitor for ITP in the EU, targeting the root cause of the disease through multi-immune modulation Paris, October 17, 2025.The European Medicines Agency’s...

Press Release: Sanofi provides update on regulatory review in the EU for…

Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host diseaseParis, October 17, 2025.The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the marketing authorisation application for Rezurock (belumosudil) for the third-line treatment of adults and pediatric patients with chronic graft-versus-host disease (cGVHD). Sanofi will seek a re-examination of the CHMP opinion.cGVHD is a...

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults…

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix is the only CML treatment with a superior efficacy and favorable safety and tolerability profile versus available first-line treatments 1 ,2 Despite available first-line treatments, 50% of patients newly diagnosed with CML miss treatment goals within one year, many of whom...

CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis

Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone 1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study 2 Lupus nephritis is a debilitating condition that severely impacts a person’s quality of life and affects more than 1.7 million people worldwide 3,4 Basel, 17 October, 2025 - Roche (SIX:...

RoboUP Pre-Launches Raccoon 2 SE on Kickstarter -- A Smart Robot Mower at the…

Founded in 2016, RoboUP has been dedicated in creating smarter, greener, and more connected living spaces. After years of helping medium and large lawn owners simplify their routines, the team realized small garden owners face their own challenges. Busy lifestyles leave little time for lawn care, and most robot mowers on the market are oversized and overpriced for small yards, making them stick to mowing by hand. For elderly homeowners, manual mowing can also be tiring and unsafe, turning a…

Adhesion Barrier Market 2025-30 Outlook Shows 7.5% CAGR as North America Leads…

North America leads, supported by widespread minimally invasive surgeries, hospital protocols, and reimbursement incentives that favor reduced post-surgical complications. Europe grows steadily with value-based care initiatives and multifunctional barrier adoption. Asia-Pacific is the fastest-growing region, driven by hospital modernization, rising surgical volumes, and expanding national reimbursement programs. Growth in the Middle East & Africa and Latin America is moderate, fueled by…

AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and…

AKYNZEO ® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors Results from the MyRisk clinical trial, accepted for publication in the Annals of Oncology, will be presented today at ESMO 2025 as an oral presentationLugano, Switzerland, October 17, 2025– Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record...

Duchenne Muscular Dystrophy Therapeutics Market Surges Toward $6.6B by 2033 as…

Browse in-depth TOC on "Duchenne Muscular Dystrophy Therapeutics Market" Browse in-depth TOC on "Duchenne Muscular Dystrophy Therapeutics Market" 70 – Tables 66 – Figures 195 – Pages Therapeutic Landscape: Molecular Therapies Redefine the Standard The market's segmentation reveals a powerful trend toward precision medicine. In 2024,Molecular-Based Therapiesdominated the landscape with45.1% market share, translating to approximatelyUS$988 million in global revenue...

Smartee Expands European Footprint with Invisible Mandibular Repositioning…

Clinical Recognition: GS Technology in Austrian Practice Clinical Recognition: GS Technology in Austrian Practice One of the highlights of the congress was a keynote lecture byDr.Thomas Felkai , a respected orthodontist and one ofAustria'searly adopters of Smartee GS mandibular Repositioning Technology. Drawing from his clinical experience, Dr. Felkai shared how this innovative protocol provides a new approach to malocclusion treatment by advancing mandible at the first phase of...

MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on…

HPH MRD testing will be performed in the company's laboratories in Hamburg, Germany, providing clinicians with potential access to next-generation MRD testing. Local availability will help ensure improved clinical implementation and timely delivery of results. All testing and data will remain with HPH in Germany, facilitating compliance with data protection and regulatory standards while supporting access. The HPH MRD test leverages whole-genome sequencing to analyze a patient's tumor tissue and…

AB Science announces the successful completion of a EUR 2.8 million private…

PRESS RELEASEAB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.8 MILLION PRIVATE PLACEMENTAB SCIENCE IS FULLY FINANCED TO FINISH PHASE 1 OF AB8939 IN AML AND TO EXECUTE AN EXPANSION PHASE TO MAXIMIZE CHANCE OF SUCCESS OF FUTURE REGISTRATION STUDYParis, October 17, 2025, 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed...

Levoit to Showcase Advanced Air Purification Solutions at KSA Baby Expo 2025

This expo debut highlights Levoit's commitment to the Saudi market, where indoor air quality is a paramount concern for parents. Featuring advanced HEPA filtration and smart sensors, Levoit products provide peace of mind by ensuring the air at home is clean and safe. This expo debut highlights Levoit's commitment to the Saudi market, where indoor air quality is a paramount concern for parents. Featuring advanced HEPA filtration and smart sensors, Levoit products provide peace of mind by...

Klea Holding confirms its hypergrowth in the Q3 2025 and its annual targets

Number of tests performed increased by +35% in Q3 and by +48% at the end of the 9M of the financial year. New revenue record in September 2025 in the Health & Wellness segment. Work resumes on the opening of the first Smart Health digital medical centre in Saudi Arabia. Confirmation of objectives: significant improvement in EBITDA, reduction of the…

AMFRESH Group Acquires 100% of TERRAMARA FRESH in Mexico, Strengthening Its…

Advanced Genetics and Farming driving the Next Generation of Table Grapes, Blueberries, and Cherries This milestone reflects the natural evolution of both organizations and their aligned strategic vision, celebrating a partnership built on trust, innovation, and a shared purpose to deliver high-quality varietal offerings to retail partners.With over 600 hectares of premium farming investment across two major production areas in Mexico, the acquisition strengthens AMFRESH’s Pacific Rim...

IBA opens the world of science and technology to secondary school girls

Its Innovat’her event brought together female students to explore careers in STEMLouvain-la-Neuve, Belgium, October 17, 2025- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, hosted theInnovat’herevent yesterday, aimed at girls in their fifth and sixth years of secondary school. The goal was to introduce them to scientific and technical careers, which remain underrepresented in the academic choices of female students.The event...

Dietary Fiber Gummies Market to Reach USD 13.44 billion by 2032, Growing At An…

The dietary fiber gummies market is experiencing remarkable growth, driven by increasing health consciousness, rising digestive health concerns, and consumer preference for convenient supplement formats. According to Credence Research "The dietary fiber gummies market was valued at USD 5.75 billion in 2024 and is anticipated to reach USD 13.44 billion by 2032, at a CAGR of 11.2% during the forecast period." This exceptional expansion reflects the growing recognition of fiber's…

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3…

/3 clinical study comparing the company’s product, recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207), to nivolumab for the neoadjuvant treatment of patients with stage Ⅱ/Ⅲ, resectable, actionable genomic aberration (AGA)-negative, non-small cell lung cancer (“NSCLC”) has been approved by the U.S. Food and Drug Administration (the “FDA”).Lung cancer is currently a malignant tumor with the highest prevalence and mortality rate in the world. According to GLOBOCAN, there...

Indolent Lymphoma Market Experiences Significant Growth Amid Evolving…

Indolent Lymphoma Market Summary Indolent Lymphoma Market Summary Discover the indolent lymphoma new treatment @New Treatments for Indolent Lymphoma Key Factors Driving the Growth of the Indolent Lymphoma Market Advancements in Targeted and Immunotherapy Treatments The development of novel therapies, including oral and injectable medications, has improved the management of indolent lymphoma. These treatments offer greater efficacy, reduced side effects, and more precise...

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025 . Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period.“We are very pleased to welcome Fred to the executive team,” said Henry Gosebruch, CEO of Galapagos. “He brings a unique combination of top-tier legal expertise,...

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet…

○ Efficacy:ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status○ In the target Phase 2 population,...

AB Science provides intitial Phase 1 data for the combination of AB8939 with…

PRESS RELEASEAB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIAParis, 16 October 2025, 9pm CETAB Science SA(Euronext - FR0010557264 - AB) today provides an update on its AB8939 program in acute myeloid leukemia (AML).The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ ...

Proya Cosmetics Shares Its Vision for the Future of Beauty at Cosmetic 360…

"I am honored to share our company's journey, our commitment, and our investments in contributing to the future of cosmetics on a global scale," said Mr. Juncheng HOU, Founder and Chairman of Proya Cosmetics. "Innovation is central to our approach, and Cosmetic 360 is a valuable opportunity for us to introduce ourselves and exchange with the international community. This year's theme, 'Predictions,' aligns well with our goal of anticipating the creation of tomorrow's cosmetics and…

Altri Comunicati